A1M Pharma AB:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:A1M Pharma AB - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11215
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:30
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スウェーデン
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
A1M Pharma AB (A1M Pharma) is a developer of a medical application for the diagnosis and treatment of pre-eclampsia and acute renal damage. The company develops and commercializes drug candidate for the diagnosis and treatment of pre-eclampsia (pandemic poisoning) and acute renal injury. It offers products such as ROSgard based on A1M (alpha-1-microglobulin), an endogenous protein with properties that captures and eliminates toxic substances from the cells metabolism. A1M Pharma’s A1M helps to prevent and ameliorate some of the damage caused by oxidative stress and inflammation; and develops novel diagnostic test for preeclampsia based on the biomarker fetal hemoglobin. The company also develops treatments for kidney damage. It also provides constitute therapeutic or diagnostic tools for various conditions and illnesses in animals and humans. A1M Pharma is headquartered in Lund, Sweden.

A1M Pharma AB – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
A1M Pharma AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
A1M Pharma AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
A1M Pharma AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
A1M Pharma AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
A1M Pharma AB, Medical Devices Deals, 2012 to YTD 2018 9
A1M Pharma AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
A1M Pharma AB, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
A1M Pharma Partnered with Clinical Trial Consultants 11
A1M Pharma Enters into Agreement with Research Toxicology Centre 12
A1M Pharma Enters into Research Agreement with CSL Behring 13
A1M Pharma Enters into Rresearch Agreement with Fred Hutchinson Cancer Research Centre 14
A1M Pharma Expands Agreement with European Pharmaceutical Company 15
A1M Pharma Enters into Partnership with Truly Translational 16
NeuroVive Pharmal And A1M Pharma Enter Into Research Agreement 17
Equity Offering 18
A1M Pharma Plans to Raise USD10.5 Million in Rights Offering of Shares 18
A1M Pharma Plans to Raise USD13.82 Million in Public Offering of Shares 19
A1M Pharma Raises USD5 Million in Rights Offering of Shares 20
A1M Pharma Raises USD3.7 Million in Rights Offering of Shares 21
A1M Pharma Raises USD3.61 Million in Rights Offering of Shares 22
A1M Pharma AB – Key Competitors 23
A1M Pharma AB – Key Employees 24
A1M Pharma AB – Locations And Subsidiaries 25
Head Office 25
Other Locations & Subsidiaries 25
Recent Developments 26
Corporate Communications 26
Aug 14, 2018: A1M Pharma names Tobias Larsson Agervald as Chief Medical Officer 26
Product News 27
02/10/2017: A1M Pharma has successfully conducted large scale manufacturing of the active substance in ROSGard and initiates GLP toxicology studies 27
Clinical Trials 28
Jun 12, 2017: A1M Pharma announces progress in the preclinical development of ROSGard 28
Mar 29, 2017: A1M Pharma: ROSGard shows strong protective effect against renal damage in connection with radiation therapy in a preclinical long-term study 29
Appendix 30
Methodology 30
About GlobalData 30
Contact Us 30
Disclaimer 30

List of Tables
A1M Pharma AB, Pharmaceuticals & Healthcare, Key Facts 2
A1M Pharma AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
A1M Pharma AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
A1M Pharma AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
A1M Pharma AB, Deals By Therapy Area, 2012 to YTD 2018 8
A1M Pharma AB, Medical Devices Deals, 2012 to YTD 2018 9
A1M Pharma AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
A1M Pharma Partnered with Clinical Trial Consultants 11
A1M Pharma Enters into Agreement with Research Toxicology Centre 12
A1M Pharma Enters into Research Agreement with CSL Behring 13
A1M Pharma Enters into Rresearch Agreement with Fred Hutchinson Cancer Research Centre 14
A1M Pharma Expands Agreement with European Pharmaceutical Company 15
A1M Pharma Enters into Partnership with Truly Translational 16
NeuroVive Pharmal And A1M Pharma Enter Into Research Agreement 17
A1M Pharma Plans to Raise USD10.5 Million in Rights Offering of Shares 18
A1M Pharma Plans to Raise USD13.82 Million in Public Offering of Shares 19
A1M Pharma Raises USD5 Million in Rights Offering of Shares 20
A1M Pharma Raises USD3.7 Million in Rights Offering of Shares 21
A1M Pharma Raises USD3.61 Million in Rights Offering of Shares 22
A1M Pharma AB, Key Competitors 23
A1M Pharma AB, Key Employees 24
A1M Pharma AB, Subsidiaries 25

List of Figures
A1M Pharma AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
A1M Pharma AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
A1M Pharma AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
A1M Pharma AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
A1M Pharma AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
A1M Pharma AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
A1M Pharma AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
A1M Pharma AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
A1M Pharma AB, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[A1M Pharma AB:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Corium International Inc (CORI):企業の財務・戦略的SWOT分析
    Summary Corium International Inc (Corium) is a commercial-stage biopharmaceutical company that produces and develops central nervous system pharmaceutical products. The company develops transdermal healthcare products with the help of Corplex technology platform using small molecules. Its products i …
  • PT Adaro Energy Tbk:企業の戦略・SWOT・財務情報
    PT Adaro Energy Tbk - Strategy, SWOT and Corporate Finance Report Summary PT Adaro Energy Tbk - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Sun Resources NL (SUR):企業の財務・戦略的SWOT分析
    Summary Sun Resources NL (Sun Resources) is an oil and gas exploration and development company. The company explores and develops crude oil and natural gas. Its services include exploration, production, and development of unconventional oil and gas resources. Its projects include Delta Oil Project, …
  • U.S. Geothermal Inc. (HTM)-エネルギー分野:企業M&A・提携分析
    Summary U.S. Geothermal Inc. (USG) is a renewable energy company. It develops and produces electricity from geothermal source. The company owns and operates geothermal power projects in Oregon, Nevada, and Idaho. USG also has interests in geothermal plants under development or exploration stages in …
  • AptarGroup Inc:企業の戦略・SWOT・財務分析
    AptarGroup Inc - Strategy, SWOT and Corporate Finance Report Summary AptarGroup Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Apollo Commercial Real Estate Finance, Inc.:企業のM&A・事業提携・投資動向
    Apollo Commercial Real Estate Finance, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Apollo Commercial Real Estate Finance, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, det …
  • Pakistan Water and Power Development Authority-エネルギー分野:企業M&A・提携分析
    Summary Pakistan Water and Power Development Authority (WAPDA) is a government-owned public authority maintaining power and water in Pakistan. It is responsible for the development of hydel power and water sector projects in Pakistan. The authority plans and executes projects and schemes for the gen …
  • Terumo BCT Inc:企業の戦略的SWOT分析
    Terumo BCT Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • Asian Citrus Holdings Ltd (73):企業の財務・戦略的SWOT分析
    Asian Citrus Holdings Ltd (73) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • KKR Financial Holdings LLC:企業の戦略・SWOT・財務情報
    KKR Financial Holdings LLC - Strategy, SWOT and Corporate Finance Report Summary KKR Financial Holdings LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Collagen Solutions Plc (COS)-医療機器分野:企業M&A・提携分析
    Summary Collagen Solutions Plc (Collagen Solutions), formerly Healthcare Investment Opportunities Plc is a medical device company that develops, manufactures and supplies medical grade collagen biomaterials and components. The company offers sourcing and supply of high grade collagen; provision of f …
  • The Prudential Insurance Company of America:企業のM&A・事業提携・投資動向
    The Prudential Insurance Company of America - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's The Prudential Insurance Company of America Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, det …
  • Capstone Turbine Corporation (CPST):電力:M&Aディール及び事業提携情報
    Summary Capstone Turbine Corporation (CPST) is an energy company. It develops, manufactures, markets, and services microturbine technology solutions and power generation systems. The company integrates air bearing technology, advanced combustion technology, and power electronics to form efficient an …
  • Medizone International Inc (MZEI):企業の財務・戦略的SWOT分析
    Summary Medizone International Inc (Medizone) is a medical device company that develops aseptic treatment. The company provides disinfectant products used in surgical and other medical treatment facilities. Its product includes AsepticSure hospital sterilization system. Medizone’s AsepticSure is an …
  • AEP Industries Inc (AEPI):企業の財務・戦略的SWOT分析
    Summary AEP Industries Inc (AEP), a subsidiary of Berry Plastics Group Inc, is a plastic packaging film provider that manufactures and markets multi-purpose and flexible packaging films. The company offers custom films such as shrink film, poly bags, tubing, construction film, sheeting, sheets, shri …
  • The Progressive Corporation:企業の戦略・SWOT・財務情報
    The Progressive Corporation - Strategy, SWOT and Corporate Finance Report Summary The Progressive Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Carisma Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Carisma Therapeutics Inc (Carisma Therapeutics), formerly CARMA Therapeutics LLC, is a biotechnology company with focus on the discovery and development of macrophage-based immunotherapeutics for the treatment of cancer. The company exploits its proprietary CAR-macrophage platform to provide …
  • Raiffeisen Bank International AG:企業の戦略・SWOT・財務情報
    Raiffeisen Bank International AG - Strategy, SWOT and Corporate Finance Report Summary Raiffeisen Bank International AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Acura Pharmaceuticals Inc (ACUR):医療機器:M&Aディール及び事業提携情報
    Summary Acura Pharmaceuticals Inc (Acura) is a specialty pharmaceutical company that researches, develops, and commercializes tamper-resistant products to prevent the abuse and misuse of medication. The company’s proprietary technologies, Aversion, Limitx and Impede, are used to prevent product tamp …
  • Ellomay Capital Ltd (ELLO):企業の財務・戦略的SWOT分析
    Summary Ellomay Capital Ltd (Ellomay), formerly NUR Macroprinters Ltd, is an energy and infrastructure consulting company that provides renewable energy, oil and gas exploration, and clean energy solutions. The company offers renewable energy services such as installation of photovoltaic plants, man …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆